Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placenta-derived mesenchymal stem cells and exosomes versus ruxolitinib for steroid-resistant acute graft-versus-host disease
IRCT20140818018842N40Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jun 2024
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, double-blind trial of placenta-derived mesenchymal stem cells and ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD) (3 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Adverse events, Complete response rate and 1 more. Started Jun 2024; status: completed.
02
Drugs
placenta-derived mesenchymal stem cellsruxolitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on IRCT20140818018842N40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N40.